The Danish drugmaker prepares to introduce its once-a-week injectable, Ozempic, as India faces rising cases of Type 2 diabetes and obesity
Danish pharmaceutical company Novo Nordisk will launch Ozempic (semaglutide) in India for patients with Type 2 diabetes.
Ozempic is a once-a-week injectable brand that was originally approved for the management of Type 2 diabetes. The drug has also gained attention for its role in weight management.
Ozempic received its first approval from the United States Food and Drug Administration (US FDA) in 2017. The company has not yet shared information regarding the price of the medicine in India. Earlier in 2025, Novo Nordisk also received approval to market WeGovy, a drug indicated for obesity management.
India records a high prevalence of Type 2 diabetes. According to available data, 101 million people in the country are living with the disease. In addition, 254 million people are reported to be affected by obesity. Both conditions have shown a twofold increase in the last decade, bringing attention to weight management challenges.